CMAC’s vision is to revolutionise the way pharmaceuticals and high value products are made. The approaches developed and adopted within CMAC have been developed through close collaboration with industry and the support of its Tier 1 partners, which includes GlaxoSmithKline, AstraZeneca, Bayer, Lilly, Novartis, Pfizer, Roche and Takeda. Established in 2011, the CMAC has a £150m funding portfolio and currently comprises more than 130 staff and researchers, including academics, post docs, and more than 30 PhD students, as well as an experienced support team.
PhD position - Enhancing virtual tablet formulation design
This is an exciting opportunity to join a dynamic research team based at the university of Strathclyde and working closely with AstraZeneca and collaborators within the Continuous Manufacturing and Advanced Crystallisation Hub (CMAC), gain experience of a range of techniques as part of your research.
Traditional pharmaceutical formulation design is driven by trial and error experimentation. With increasing optimisation of clinical development, designing robust formulations and well characterised manufacturing processes can become a rate limiting step to making new medicines routinely available to patients. This project will develop constitutive property and performance models to predict the contribution of formulation components to bulk strength, tablet porosity, pore size and disintegration performance. The use of materials databases combined with these predictive process and product models will have the potential to dramatically optimise and accelerate the formulation design phase in the development of new medicines.
To apply for this project you should have a background in chemistry, physics, pharmaceutical science, material science, chemical engineering, mechanical engineering, or similar. You will need to have a passion for research, multidisciplinary collaboration, and collaboration with industrial stakeholders.
The offered studentship covers home tuition fees, research/training costs, and provides a stipend for 4 years. Candidates eligible for home fees are UK or Irish nationals, applicants with a settled or pre-settled status in the UK under the EU Settlement Scheme, and applicants with indefinite leave to remain in the UK. We also welcome applications from EU or international candidates who can provide evidence of their ability to fund the fee difference.
Applicants can express their interest for this project or ask any questions by emailing firstname.lastname@example.org and email@example.com and attaching their CV.
Deadline for expression of interest: May 14th
PhD position - The Surface Properties of Pharmaceuticals
This industrially co-funded interdisciplinary project presents an exciting opportunity for an ambitious scientist or engineer to work across the boundaries of chemistry, physics and engineering, with opportunities to develop a broad portfolio of skills and a strong professional network in academia and industry. A combination of polarised Raman spectroscopy and small angle X-ray scattering techniques will be used to study the surfaces of crystalline drugs, to determine how surface properties influence their behaviour in medicines.
PhD position - Discovery and Applications of Novel Solid-State Structures: Water Bridge Salt Forms
This project is fully funded University of Strathclyde Research Excellence Award and 42 month project duration
Candidates should hold/expect to obtain 2:1 Honour degree or overseas equivalent .
The project aims to improve our ability to identify and exploit crystalline hydrated salt forms that are in a unique solid-state arrangement known as a “water bridge”. .... more
MIT-CMAC International Symposium on Continuous Manufacturing of Pharmaceuticals
An Integrated Ecosystem for Transforming Medicines Manufacturing
18th February 2021, 12.30-17.00 GMT
This symposium brings together pharmaceutical industrialists, regulators, policy makers and academics to look at how the community can grow medicines manufacturing in the UK and accelerate the adoption of advanced manufacturing and digital technologies. To achieve this we need an integrated approach, harnessing the combined efforts of the stakeholders to lead the transformation that will enhance quality, cost and sustainability of medicines manufacture, ultimately for the benefit of patients. .... more
Laminar and UK/IRE Distributor Analytik Join CMAC Future Manufacturing Research Hub
Continuous flow chemical reactor manufacturer Laminar Co Ltd (Jungwon-gu, Republic of Korea), represented in the UK and Ireland by Analytik Ltd (Cambridge, UK), have joined the CMAC Future Manufacturing Research Hub as tier 2 members from October 2020..... more
Launch of CMAC - Huxley Bertram Partnership to Support Compaction Simulation Research and Services
CMAC are pleased to announce that following the recent establishment of our new Compaction Simulation Pilot Test Facility, we can now offer Compaction Simulation Research Services through our National Facility Team. This is supported by a new partnership between Huxley Bertram and the CMAC Future Manufacturing Research Hub at the University of Strathclyde (Glasgow, UK). .... more